Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Gen Intern Med ; 37(8): 1943-1952, 2022 06.
Article in English | MEDLINE | ID: mdl-35319081

ABSTRACT

BACKGROUND: After mild COVID-19, some outpatients experience persistent symptoms. However, data are scarce and prospective studies are urgently needed. OBJECTIVES: To characterize the post-COVID-19 syndrome after mild COVID-19 and identify predictors. PARTICIPANTS: Outpatients with symptoms suggestive of COVID-19 with (1) PCR-confirmed COVID-19 (COVID-positive) or (2) SARS-CoV-2 negative PCR (COVID-negative). DESIGN: Monocentric cohort study with prospective phone interview between more than 3 months to 10 months after initial visit to the emergency department and outpatient clinics. MAIN MEASURES: Data of the initial visits were extracted from the electronic medical file. Predefined persistent symptoms were assessed through a structured phone interview. Associations between long-term symptoms and PCR results, as well as predictors of persistent symptoms among COVID-positive, were evaluated by multivariate logistic regression adjusted for age, gender, smoking, comorbidities, and timing of the survey. KEY RESULTS: The study population consisted of 418 COVID-positive and 89 COVID-negative patients, mostly young adults (median age of 41 versus 36 years in COVID-positive and COVID-negative, respectively; p = 0.020) and healthcare workers (67% versus 82%; p = 0.006). Median time between the initial visit and the phone survey was 150 days in COVID-positive and 242 days in COVID-negative patients. Persistent symptoms were reported by 223 (53%) COVID-positive and 33 (37%) COVID-negative patients (p = 0.006) and proportions were stable among the periods of the phone interviews. Overall, 21% COVID-positive and 15% COVID-negative patients (p = 0.182) attended care for this purpose. Four surveyed symptoms were independently associated with COVID-19: fatigue (adjusted odds ratio 2.14, 95% CI 1.04-4.41), smell/taste disorder (26.5, 3.46-202), dyspnea (2.81, 1.10-7.16), and memory impairment (5.71, 1.53-21.3). Among COVID-positive, female gender (1.67, 1.09-2.56) and overweight/obesity (1.67, 1.10-2.56) were predictors of persistent symptoms. CONCLUSIONS: More than half of COVID-positive outpatients report persistent symptoms up to 10 months after a mild disease. Only 4 of 14 symptoms were associated with COVID-19 status. The symptoms and predictors of the post-COVID-19 syndrome need further characterization as this condition places a significant burden on society.


Subject(s)
COVID-19 , Adult , COVID-19/complications , COVID-19/epidemiology , Cohort Studies , Female , Humans , Outpatients , Prospective Studies , SARS-CoV-2 , Young Adult , Post-Acute COVID-19 Syndrome
2.
Braz. j. infect. dis ; 24(3): 256-260, May-June 2020. tab
Article in English | LILACS, Coleciona SUS | ID: biblio-1132443

ABSTRACT

ABSTRACT The purpose of this study was to estimate the prevalence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections in western French Guiana and to analyze associated factors with both infections. A retrospective study was conducted in a sexually transmitted infections clinic in 2017. Women (n = 338) were tested by real-time polymerase chain reaction for vaginal, anal and throat CT and NG infections. Men (n = 192) were evaluated using urine specimens. Socio-demographic and sexual behaviour data were collected by nurses with a structured questionnaire. The prevalence of CT and NG infections among women were 24.3% and 13.3%, respectively, and 12.0% and 7.3% among men. Women aged under 25 years had a higher risk of CT and NG infections than women aged 35 years or more. Another risk factor for CT infection was low educational level, and occasional unprotected sex for NG infection. CT and NG infections were associated with reporting symptoms among men. Very high prevalences of CT and NG infections among women and men were found, which suggest that a large-scale screening strategy should be implemented in French Guiana.


Subject(s)
Adult , Female , Humans , Male , Chlamydia Infections/epidemiology , Gonorrhea/epidemiology , Chlamydia trachomatis , Neisseria gonorrhoeae , Prevalence , Retrospective Studies , French Guiana/epidemiology
3.
Braz J Infect Dis ; 24(3): 256-260, 2020.
Article in English | MEDLINE | ID: mdl-32442426

ABSTRACT

The purpose of this study was to estimate the prevalence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections in western French Guiana and to analyze associated factors with both infections. A retrospective study was conducted in a sexually transmitted infections clinic in 2017. Women (n=338) were tested by real-time polymerase chain reaction for vaginal, anal and throat CT and NG infections. Men (n=192) were evaluated using urine specimens. Socio-demographic and sexual behaviour data were collected by nurses with a structured questionnaire. The prevalence of CT and NG infections among women were 24.3% and 13.3%, respectively, and 12.0% and 7.3% among men. Women aged under 25 years had a higher risk of CT and NG infections than women aged 35 years or more. Another risk factor for CT infection was low educational level, and occasional unprotected sex for NG infection. CT and NG infections were associated with reporting symptoms among men. Very high prevalences of CT and NG infections among women and men were found, which suggest that a large-scale screening strategy should be implemented in French Guiana.


Subject(s)
Chlamydia Infections/epidemiology , Chlamydia trachomatis , Gonorrhea/epidemiology , Neisseria gonorrhoeae , Adult , Female , French Guiana/epidemiology , Humans , Male , Prevalence , Retrospective Studies
4.
Rev Med Suisse ; 16(690): 724-730, 2020 Apr 15.
Article in French | MEDLINE | ID: mdl-32301306

ABSTRACT

Biological treatments are a revolution in the management of many diseases and their development, with the marketing of many new biologics, challenges practitioners in assessing the risk of infectious complications. A rigorous evaluation is required with the introduction of prophylaxis, vaccinations or specific clinical monitoring.


Les traitements biologiques sont une révolution dans la prise en charge de nombreuses pathologies et leur développement, marqué par la mise sur le marché de nombreux nouveaux biologiques, met au défi les praticiens dans l'évaluation du risque de complications infectieuses. Une évaluation rigoureuse est requise avec l'introduction de prophylaxies, de vaccinations ou d'un suivi clinique spécifique.


Subject(s)
Biological Products/adverse effects , Disease Susceptibility , Immunosuppressive Agents/adverse effects , Infections/etiology , Pre-Exposure Prophylaxis/methods , Drug Administration Schedule , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...